Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study

<p>Abstract</p> <p>Background</p> <p>Antipsychotic are the cornerstone in the treatment of schizophrenia. They also have a number of side-effects. Constipation is thought to be common, and a potential serious side-effect, which has received little attention in recent literature.</p> <p>Method</p> <p>We performed a retrospective study in consecutively admitted patients, between 2007 and 2009 and treated with antipsychotic medication, linking different electronic patient data to evaluate the prevalence and severity of constipation in patients with schizophrenia under routine treatment conditions.</p> <p>Results</p> <p>Over a period of 22 months 36.3% of patients (99) received at least once a pharmacological treatment for constipation. On average medication for constipation was prescribed for 273 days. Severe cases (N = 50), non-responsive to initial treatment, got a plain x-ray of the abdomen. In 68.4% fecal impaction was found.</p> <p>Conclusion</p> <p>A high prevalence of constipation, often severe and needing medical interventions, was confirmed during the study period. Early detection, monitoring over treatment and early intervention of constipation could prevent serious consequences such as ileus.</p

Laser-assisted nuclear decay spectroscopy of 176,177,179Au

A study of the laser-ionized and mass-separated neutron-deficient isotopes Au-176,Au-177,Au-179 was performed using the Resonance Ionization Laser Ion Source and the Windmill detection setup at ISOLDE, CERN. New and improved data on complex fine-structure alpha decays of the three isotopes were deduced, providing insight into the low-lying levels in the daughter nuclei Ir-172,Ir-173,Ir-175. New information on the properties of beta-decay daughter products Pt-177,Pt-179 was also obtained. From the first in-source laser spectroscopy measurements of the hyperfine structure in the atomic 267.6-nm transition of Au-176, the nuclear magnetic moments for both high- and low-spin alpha-decaying states were deduced. Together with the values determined from the additivity relations, they were used to propose the most probable spins and configurations for both states. The a-decay branching ratios were determined as b(alpha)(Au-176(1s)) = 58(5)% and b(alpha)(Au-176(hs)) = 29 (5)%

Biodistribution and tolerance of intravenous iodine-131-labelled hypericin in healthy dogs

Hypericin (Hyp) is a necrosis-avid compound that can be efficiently labelled with radioiodine for both diagnostic and therapeutic purposes. Before I-131-Hyp can be considered as a clinically useful drug in a combination therapy for canine cancer patients, evaluation of its toxicity is necessary. The aim of this study was to investigate the biodistribution and tolerance of a single dose administration of I-131-Hyp. Three healthy dogs were included. I-131-Hyp at a dose of 0.2 mg/kg and an activity of 185 MBq was intravenously injected. The effects on physical, haematological and biochemical parameters were characterized and the biodistribution and elimination pattern, the effective half-life and dose rate were assessed. Drug-related adverse events were limited to mild gastrointestinal signs, resolving within 48 hours. No significant differences were found in blood haematology and serum biochemistry before and after treatment. Following administration, highest percentage of injected dose (%ID +/- SD) was found in the liver (5.5 +/- 0.33), the lungs (4.17 +/- 0.14) and the heart (3.11 +/- 0.78). After 24 hours, highest %ID was found in colon (4.25 +/- 1.45) and liver (3.45 +/- 0.60). Clearance from all organs was effective within 7 days. Effective half-life was established at 80 hours, and the dose rate fell below <20 Sv/h at 1 m within 1 day. The current study reveals that single dose treatment with I-131-Hyp at the described dose is well tolerated by healthy dogs and supports the use of radioiodinated hypericin in a combination therapy for canine cancer patients